Know Cancer

or
forgot password

Rituximab in Primary LPHD (RIPL) - First Line Therapy for Patients With Lymphocyte Predominant Hodgkin´s Disease (LPHD) in Clinical Stage IA Using the Monoclonal Anti-CD20 Antibody Rituximab.


Phase 2
18 Years
75 Years
Not Enrolling
Both
Lymphocyte Predominant Hodgkin´s Lymphoma (LPHD)

Thank you

Trial Information

Rituximab in Primary LPHD (RIPL) - First Line Therapy for Patients With Lymphocyte Predominant Hodgkin´s Disease (LPHD) in Clinical Stage IA Using the Monoclonal Anti-CD20 Antibody Rituximab.


Inclusion Criteria:



- lymphocyte predominant Hodgkin´s lymphoma (histologically proven)

- clinical stage IA (without risk factors: large mediastinal mass, extranodal
involvement, ESR > 50mm/h)

- age 18 - 75

- WHO performance status 0-3

- normal organ function

- written informed consent

Exclusion Criteria:

- classical Hodgkin´s lymphoma

- composite lymphoma

- leucocytes < 3000/µl

- thrombocytes < 100.000/µl

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Principal Investigator

Andreas Engert

Investigator Role:

Principal Investigator

Investigator Affiliation:

Universitiy of Cologne

Authority:

Germany: Federal Institute for Drugs and Medical Devices

Study ID:

RIPL

NCT ID:

NCT00346684

Start Date:

July 2006

Completion Date:

Related Keywords:

  • Lymphocyte Predominant Hodgkin´s Lymphoma (LPHD)
  • Lymphoma
  • LPHD
  • Rituximab
  • Hodgkin Disease
  • Lymphoma

Name

Location